Thymosin Beta-4 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Thymosin Beta-4 for Health & Longevity

Created on 07/15/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 – Audit

Thymosin β4 is a natural repair protein that helps cells move to injuries and rebuild tissue. Its strongest human evidence is for the eye surface and slow-healing skin wounds; popular muscle and joint recovery uses rest on animal data only. Key concerns are possible hidden-cancer growth, unknown long-term safety, and unregulated product quality. (Full Review)

Protocol

Loading
2–2.5 mg 2×/week
Subcutaneous, 4–6 weeks
Maintenance
2–2.5 mg every 1–2 weeks
Lower dose after loading
Administration
Subcutaneous injection
Weekly total split into 2 doses
Time to effect
Tissue repair
2–6 weeks
Gradual onset over a course
Loading course
4–6 weeks
Before maintenance dosing
Plasma half-life
A few hours
Effects outlast blood levels

Benefits

Contraindications
  • Active or recent cancer (within ~5 years)
  • Pregnancy or breastfeeding
  • Active proliferative eye disease
  • Drug-tested athletes (WADA-banned)
    •
Key Interactions
  • Anti-angiogenic cancer therapies (bevacizumab, sunitinib, lenalidomide)
  • Long-term high-dose NSAIDs (ibuprofen, naproxen) or corticosteroid creams
  • BPC-157 stacking
  • Anabolic regimens (growth hormone, insulin-like growth factor)
    •

Risk & Side Effects

  • High: Unregulated product quality and contamination; injection-site reactions
    •
  • Medium: Potential promotion of tumor growth and metastasis
    •
  • Low: Immunogenicity
    •
  • Speculative: Excessive or misplaced angiogenesis; unknown long-term systemic effects
    •

Monitoring

Marker Target Why
Complete blood count (CBC) Within normal limits Screens for occult blood cancers and infection
hs-CRP < 1.0 mg/L (target < 0.5) Gauges baseline inflammation and anti-inflammatory response
Comprehensive metabolic panel ALT/AST in range; eGFR > 90 Confirms liver and kidney function
Fasting glucose / HbA1c Glucose 75–85 mg/dL; HbA1c < 5.4% Impaired glucose control slows healing
Tumor markers (e.g., PSA) Age-adjusted reference range Screens for occult malignancy

Cadence: Baseline before first dose; recheck at 4–6 weeks, then every 3–6 months if use continues

Qualitative Assessment

  • Recovery and function: healing of the targeted injury and return of range of motion
  • Energy and well-being: energy levels and subjective recovery between sessions
  • Warning signs: any new lump, unexplained pain, or unusual bleeding prompts stopping and medical review
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.